Search clinical trials for: Aliskerin/Valsartan and Rampiril

Total 732 results

University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
Novartis Pharmaceuticals

Completed

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)

Heart Failure

Russian Federation, Germany, Poland
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Novartis

Completed

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Hypertension

United States, Argentina, Colombia, France, Germany, India, Spain
Novartis

Completed

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Hypertension

Singapore, Hungary, Czech Republic, United Kingdom
Novartis

Completed

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus (ViVID)

Hypertension

United States
Nantes University Hospital

Terminated

Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Heavy Proteinuria

France
Novartis

Completed

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients (ALIAS)

Essential Hypertension

France
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Novartis Pharmaceuticals

Completed

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)

Acute Myocardial Infarction

China, United States, South Africa, Italy, Spain, Croatia, Czechia, Hungary, Romania, Taiwan, Belgium, Germany, Netherlands, Austria, Denmark, United Kingdom, Thailand, Argentina, Israel, Australia, Bulgaria, France, Greece, Russian Federation and more
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI); University of Washington

Terminated

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Endothelial Dysfunction | Oxidative Stress

United States
HeartDrug Research LLC
Novartis

Unknown

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Diabetes Mellitus

United States
John Paul II Hospital, Krakow

Not yet recruiting

The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction (CRACOVIA-HF)

Heart Failure With Moderately Reduced Ejection Fraction
Brigham and Women's Hospital

Terminated

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Insulin Sensitivity | Diastolic Function | Aortic Compliance

United States
Novartis

Completed

Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg

Hypertension

China, India, Thailand
Novartis

Completed

Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.

Healthy

United States
Novartis

Completed

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Healthy

United States
Columbia University
Novartis Pharmaceuticals

Terminated

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Diabetic Nephropathy | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerulonephritis, Membranous | Hypertensive Nephrosclerosis | Proteinuric Kidney Disease | Glomerulopathy (Obesity-associated)

United States
An-Najah National University

Recruiting

Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography

Chronic Kidney Diseases | Ischemic Heart Disease | Contrast-induced Nephropathy

Palestinian Territory, occupied
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

End Stage Renal Failure on Dialysis | Complication of Hemodialysis

United States
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
Wayne State University
Novartis

Unknown

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)

Hypertension

United States
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Chronic Heart Failure
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PRECISION-BP)

Cardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone System

United States
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

Cardiovascular Diseases | Diabetes Mellitus | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism | Natriuretic Peptides

United States
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Novartis Pharmaceuticals

Completed

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Hypertension

Sweden, Belgium, Hungary, India, Italy, Poland, Turkey, United States, Brazil, France, South Africa
Novartis Pharmaceuticals

Completed

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Heart Failure

United States
Yuhan Corporation

Completed

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis

Completed

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Hypertension
Bio-innova Co., Ltd

Not yet recruiting

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

Healthy Subjects
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Diabetic Kidney Disease

China
Hannover Medical School
DLR German Aerospace Center

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure (ARNI-Sy)

Heart Failure

Germany
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
Novartis

Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Hypertension

United States
LanZhou University

Unknown

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

Hypertension
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
The Children's Hospital of Zhejiang University...

Unknown

Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules

Henoch Schönlein Purpura Nephritis

China
Kitakyushu-Tsuyazaki Hospital

Completed

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

Hypertension

Japan
University of Zurich
Novartis Pharmaceuticals

Completed

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (VASCEND)

Heart Failure

Switzerland
Guangdong Provincial People's Hospital

Unknown

Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure (ESARHD-HF)

Heart Failure | Hemodialysis Complication

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Viatris Inc.

Not yet recruiting

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Bioequivalence Study

Thailand
University of Leipzig

Active, not recruiting

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure (ARNI-PVA)

Heart Failure With Reduced Ejection Fraction

Germany
Novartis Pharmaceuticals

Completed

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure (PROVIDE-HF)

Heart Failure, Systolic

United States

3

Subscribe